Protocol Ledger

NCT04510597 · Phase III · RECRUITING

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Interventional Phase III clinical trial protocol NCT04510597 sponsored by SWOG Cancer Research Network in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-08 Enrollment: 364 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04510597
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)364 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04510597
Protocol FieldVerified Registry Value
NCT IdentifierNCT04510597
Consolidated Lead SponsorSWOG Cancer Research Network
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment364 participants (ESTIMATED)
Registered Start Date2021-03-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI